Adaptive Biotechnologies (ADPT) Invested Capital (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Invested Capital data on file, last reported at $222.1 million in Q1 2026.

• Quarterly Invested Capital rose 15.56% year-over-year to $222.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.1 million (up 15.56% YoY) and the FY2025 annual result came in at $223.4 million, up 9.88% from the prior year.
• Invested Capital declined to $222.1 million in Q1 2026 per ADPT's latest filing, from $223.4 million in the prior quarter.
• The five-year high for Invested Capital was $553.3 million in Q1 2022, with the low at $182.6 million in Q2 2025.
• Average Invested Capital over 5 years is $322.8 million, with a median of $274.8 million recorded in 2024.
• Year-over-year, Invested Capital plunged 39.03% in 2024 and advanced 15.56% in 2026.
• Adaptive Biotechnologies' Invested Capital stood at $464.1 million in 2022, then tumbled by 33.57% to $308.3 million in 2023, then slumped by 34.04% to $203.4 million in 2024, then gained by 9.88% to $223.4 million in 2025, then fell by 0.58% to $222.1 million in 2026.
• Business Quant data shows ADPT's Invested Capital at $222.1 million in Q1 2026, $223.4 million in Q4 2025, and $206.9 million in Q3 2025.